With the disclosure of the annual reports of listed companies, the positions of private placement leaders have also surfaced, and the every move of Feng Liu, managing director of Gaoyi assets, has attracted much market attention.
According to the positions disclosed at present, Feng Liu’s three stocks are traditional Chinese medicine stocks. In the fourth quarter of last year, he increased his position by China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , and adhered to Beijing Tongrentang Co.Ltd(600085) and Jiangsu Kanion Pharmaceutical Co.Ltd(600557) , with a total market value of 4.65 billion yuan at the end of the period. These stocks are “heart water stocks” that he has held for many quarters. From the end of last year to the beginning of this year, the traditional Chinese medicine sector ushered in a wave of sharp rise, and Feng Liu’s layout also made a lot of money.
Feng Liu continues to increase warehouse China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999)
On March 25, China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) disclosed the annual report of 2021. From the perspective of its top ten circulating shareholders, gaoyilinshan No. 1 Yuanwang fund managed by Feng Liu increased its position by 7 million shares in the fourth quarter of last year, and its shareholding increased to 42 million shares at the end of the period, with a market value of 1.438 billion yuan, ranking the third largest circulating shareholder.
This has been Feng Liu’s position increase for the last three consecutive quarters China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , which shows that he is optimistic about the stock. As early as the first quarter of 2017, Feng Liu bought China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) 8.8 million shares, but withdrew after only one or two quarters. Until the second quarter of 2021, we increased our positions and entered the top ten circulating shareholders, holding 21.5 million shares at that time; In the third quarter, the position was increased by 13.5 million shares, and the shareholding increased to 35 million shares at the end of the quarter; In the fourth quarter, it continued to increase its position by 7 million shares, and its shareholding increased to 42 million shares at the end of the year.
In this process, China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) ‘s share price showed outstanding performance, and of course, it fluctuated greatly. It fluctuated and rose from around 23 yuan and 24 yuan at the beginning of the second quarter of last year, and also fell sharply in July and October. However, by the end of last year, it rose strongly to around 34 yuan. The biggest increase was at the end of the year, in which some trading days pulled out the daily limit. The stock rose as high as 42.73% from the second quarter of last year to the end of the year, which shows that Feng Liu also made a lot of money in this process.
Meanwhile, at the beginning of this year, the traditional Chinese medicine sector rose sharply, China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) continued to maintain the rising trend. As of the closing on March 25, it closed at 37.89 yuan / share, with a total market value of 37.1 billion yuan, an increase of 10.66% this year.
China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) last year’s net profit was 2.047 billion yuan
Let’s take a look at the charm of China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) after all. In a weak market, the stock price can maintain its rise and attract Feng Liu to add positions at the same time.
Statistics show that China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) is a large state-controlled listed pharmaceutical company. Its main core business is OTC and traditional Chinese medicine prescription drugs. OTC core products occupy a high market share in cold, gastrointestinal, skin, pediatrics, cough and orthopedic drugs; Prescription drug products are in the forefront of the Chinese market in the fields of traditional Chinese medicine formula granules, cardio cerebrovascular, anti-tumor and anti infection.
According to the annual report, China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) 2021 achieved an operating revenue of 15.32 billion yuan, a year-on-year increase of 12.34%; The net profit attributable to the shareholders of the listed company was 2.047 billion yuan, a year-on-year increase of 28.13%; The basic earnings per share is 2.09 yuan / share.
The company also announced the profit distribution plan for 2021 as follows: taking 978.9 million shares as the base, the company will distribute a cash dividend of 8.60 yuan (including tax) to all shareholders for every 10 shares.
The company said that in the revenue of 2021, CHC health consumer goods business realized an operating revenue of 9.276 billion yuan, a year-on-year increase of 17.72%. The operating revenue of prescription drug business was 5.35 billion yuan, with a year-on-year increase of 2.76%. Among them, the specialty and traditional Chinese medicine formula particle business achieved rapid growth, the anti infection business was limited, and the decline in the impact of anti-virus and centralized purchase policies continued. It is expected that the follow-up business will show restorative growth driven by the continuous development of new products. The net cash flow from operating activities was 1.871 billion yuan, a year-on-year decrease of 15.89%, which basically remained stable.
Ping An Securities believes that China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) is the characteristic “self diagnosis and treatment + prescription drugs” platform of China Resources Group. It has a rich product line and is a leader in China’s traditional Chinese medicine industry. At present, the number of varieties with annual sales of more than 100 million yuan has reached 21, of which CHC business covers many categories such as cold, gastrointestinal and skin. “999” brand enjoys high recognition, and the core products 999 Ganmaoling and Sanjiu Weitai rank in the forefront of the Chinese market; Prescription drug business covers cardio cerebrovascular, tumor and other treatment fields. Shenfu injection, cinobufagin and other products enjoy a high reputation in the industry. At the same time, the heavy support policies of traditional Chinese medicine have been issued one after another, and the equity incentive goal of the company shows development confidence. In addition, CHC business continues to improve and expand, and traditional Chinese medicine formula particles have become a new growth point. Through extension mergers and acquisitions, the company has successively supplemented “Tianhe”, “Shunfeng”, “Aonuo” and other brands to further strengthen terminal coverage.
Feng Liu 2.9 billion position stick to Beijing Tongrentang Co.Ltd(600085)
Glenn also newly joined the top ten stocks
Beijing Tongrentang Co.Ltd(600085) in the annual report disclosed on March 25, Gao yilinshan No. 1 Yuanwang fund managed by Feng Liu still stuck to the stock at the end of the fourth quarter of last year, holding 65 million shares with a market value of 2.924 billion yuan, ranking the second largest circulating shareholder. It is worth noting that the China EU medical and health mixed fund managed by Glenn has also entered the top ten Beijing Tongrentang Co.Ltd(600085) companies, holding 228322 million shares, with a market value of 1.027 billion yuan at the end of the period; However, the pioneer of China Europe times managed by Zhou Weiwen reduced its shareholding to Tsinghua Tongfang Co.Ltd(600100) shares, with a market value of 270 million yuan at the end of the period.
In fact, Feng Liu has held Beijing Tongrentang Co.Ltd(600085) for one and a half years. He was the top ten circulating shareholders of the stock in the third quarter of 2020. At that time, he held 50 million shares, and the market value of his shares at the end of the period was 1.349 billion yuan; By the end of 2020, Feng Liu added 15 million shares and increased his shareholding to 65 million shares. The market value of his shareholding at the end of the period was 1.554 billion yuan. Since then, Feng Liu has always adhered to the stock in 2021, but the number of shares has not increased. However, due to the rise of Beijing Tongrentang Co.Ltd(600085) ‘s share price, the market value of his position rose to 2.924 billion yuan by the end of the fourth quarter of last year, almost doubling.
In terms of share price performance, the stock rose by nearly 69% from the third quarter of 2020 to the end of the fourth quarter of 2021, when Feng Liu held Beijing Tongrentang Co.Ltd(600085) . From the initial 27 yuan to 45 yuan by the end of 2021, of course, the fluctuation during this period is also very large. There was a main rising wave in May and December 2021.
At the beginning of this year, the performance of the traditional Chinese medicine sector was outstanding, Beijing Tongrentang Co.Ltd(600085) also increased significantly, once reaching the stage high of 55.45 yuan, but then decreased greatly. By the closing on March 26, the stock closed at 43.39 yuan / share, with a total market value of 59.5 billion yuan.
Beijing Tongrentang Co.Ltd(600085) last year’s net profit of 1.227 billion yuan
Beijing Tongrentang Co.Ltd(600085) is a well-known time-honored brand of traditional Chinese medicine, represented by Angong Niuhuang Pill, Tongren Niuhuang Qingxin pill and Tongren Dahuoluo pill.
Let’s take a look at the performance of Beijing Tongrentang Co.Ltd(600085) the leader of traditional Chinese medicine. The annual report shows that Beijing Tongrentang Co.Ltd(600085) achieved an operating revenue of 14.603 billion yuan in 2021, a year-on-year increase of 13.86%; The net profit was 1.227 billion yuan, a year-on-year increase of 19%; The basic earnings per share is 0.90 yuan. Among them, Beijing Tongrentang Co.Ltd(600085) top five series products had an operating revenue of 4.116 billion yuan, a year-on-year increase of 15.41%; Gynecology is the product with the largest increase in revenue, with a revenue of 380 million yuan in 2021, a year-on-year increase of 23.83%.
It is worth noting that Beijing Tongrentang Co.Ltd(600085) also plans to pay dividends this time. The company plans to pay a cash dividend of 2.9 yuan (including tax) for every 10 shares.
According to the annual report, 6 Sinopec Oilfield Equipment Corporation(000852) 021’s operating revenue increased by 13.86% over the same period of last year, mainly due to the increase of product sales. In 2021, the traditional Chinese medicine market showed a steady growth trend. Covid-19 epidemic reshaped the cognition of traditional Chinese medicine, and the inheritance and development of traditional Chinese medicine became the main tone. Although still affected by the covid-19 epidemic, the company’s retail stores adhere to innovation and promote store sales business. Overseas companies actively explore new ways of traditional Chinese medicine serving the international epidemic to overcome the impact of the epidemic. In addition, the company promoted the comprehensive improvement of quality and efficiency, chose the best opportunity to purchase raw materials of traditional Chinese medicine, and adjusted the inventory structure. Through various refined management measures, the company’s operating revenue resumed growth and the cost was effectively controlled during the reporting period.
For the annual report of Beijing Tongrentang Co.Ltd(600085) and Tianfeng Securities Co.Ltd(601162) comments, the company deeply implements the large variety strategy, reasonably optimizes the allocation of resources, and comprehensively promotes unsaturated marketing through market control. In 2021, focusing on the actual needs of production, operation and quality, the company carried out research work around innovative product development, cultivation of famous and high-quality varieties, tackling key problems in production and quality, construction of traceability system, reserve of key technologies, inheritance and development of processing technology, invested 176 million yuan in R & D, with a year-on-year increase of 27.38%, formed an overall plan for 16 key varieties, and launched the research work on 14 varieties such as Tongren Niuhuang Qingxin pill and Morinda officinalis oligosaccharide capsule, At the same time, deepen cooperation with external scientific research institutions and promote the transformation of scientific research achievements. In addition, the company continued to promote the improvement of operation quality and made steady efforts in the pharmaceutical business sector. In 2021, 42 subordinate stores of Beijing Tongrentang Co.Ltd(600085) commerce were added, and there were 920 stores by the end of 2021.
